. Kj



Clinical Kidney Journal, 2020, vol. 13, no. 4, 722

doi: 10.1093/ckj/sfz009 Advance Access Publication Date: 11 February 2019 Erratum

ERRATUM

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

William G. Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J. Hauske, Jyothis T. George, Jennifer B. Green, Martin J. Landray, Colin Baigent and Christoph Wanner

Clinical Kidney Journal, Volume 11, Issue 6, 1 December 2018, Pages 749–761, https://doi.org/10.1093/ckj/sfy090

In the footnote of Figure 5 "Empagliflozin 0/4687 vs placebo 1/2333 participant reported Fournier's gangrene (perineal necrotizing fasciitis)" has been replaced with "Empagliflozin 0/4687 vs placebo 0/2333 participants reported Fournier's gangrene (perineal necrotizing fasciitis)".

© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.